Thalamic stroke: Symptoms, causes, treatment, and outlook

Late-Breaking Clinical Trial Results Announced At The VEINS 2023

LAS VEGAS, Oct. 30, 2023 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the Late-Breaking Clinical Trials session at The VEINS conference, hosted at Wynn Las Vegas.

The VEINS (Venous Endovascular INterventional Strategies) is an annual venous education symposium that brings together a global, multispecialty faculty to present a comprehensive variety of talks and case presentations focused on venous care. Attendees include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists. Below are highlights of this morning's 4 late-breaking clinical trial presentations.

1-Year Clinical Outcomes of Deep Vein Thrombosis Patients Treated With Mechanical Thrombectomy: Analysis of the CLOUT RegistryPresented by David J. Dexter, MD

Long-term, prospective outcome data after mechanical thrombectomy (MT) for deep vein thrombosis (DVT) are lacking. The CLOUT (ClotTriever Outcomes) registry is a prospective, multicenter study evaluating patient outcomes for proximal lower extremity DVT treated with the ClotTriever system (Inari Medical).

CLOUT is the largest MT study in the field of DVT, and although positive results have been previously published, this is the first report of 1-year outcomes for all available patients. Patients in CLOUT were aged ≥ 18 years and enrolled regardless of bilateral disease, duration of symptoms, prior treatment failure for the current DVT event, or contraindications to thrombolytic therapy. A total of 310 patients completed the 1-year follow-up visit.

One year after MT, moderate-to-severe postthrombotic syndrome (PTS; Villalta score ≥ 10) was observed in 8.8% of treated limbs. The overall PTS rate (Villalta score ≥ 5) was 19.3%. Venous patency, as measured by the presence of flow with normal or partial compressibility on duplex ultrasound, was observed in 94.2% of cases. Additionally, significant improvements from baseline in revised Venous Clinical Severity Score, Numeric Pain Rating Scale score, and EQ-5D questionnaire score were demonstrated.

In the real-world, all-comer CLOUT registry, 1-year outcomes demonstrate a low rate of PTS following treatment with the ClotTriever system, which was complemented by patient-centric improvements in symptom relief and quality of life. Study follow-up through 2 years is ongoing. These favorable clinical outcomes highlight the need for randomized controlled trial data comparing MT with standard of care anticoagulation treatment. The recently initiated randomized controlled DEFIANCE trial (NCT05701917) will compare the ClotTriever system to anticoagulation for the treatment of symptomatic iliofemoral DVT.

Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System: The VIVID TrialPresented by: Mahmood Razavi, MD

The Duo Venous Stent System, comprised of the Duo Hybrid and Duo Extend stents, is uniquely designed for the varying anatomical and mechanical demands of the iliofemoral venous segment. The purpose of the VIVID study was to investigate the safety and efficacy of the Duo Venous Stent System for the treatment of patients with non-malignant iliofemoral occlusive disease.

VIVID was a prospective, multi-center, single-arm study conducted in the United States and Poland. Study centers enrolled patients with non-thrombotic, acute thrombotic, or chronic post-thrombotic clinically significant venous outflow obstruction. Patients were required to have at least one of the following clinical indicators: CEAP ³3, VCSS pain score ³2, and/or suspected and symptomatic deep vein thrombosis. Performance goals were established from published, peer reviewed scientific literature. The primary safety endpoint was freedom from major adverse events at 30 days post-index procedure. The primary efficacy endpoint was primary patency of the stented segment at 12 months. The primary efficacy performance goal was derived based on enrollment distribution within the three disease states. Primary endpoints were adjudicated by a clinical events committee and/or core laboratory. Secondary and observational endpoints include symptom relief, primary-assisted patency, secondary-assisted patency, and device success. Patients remain in follow-up through 36 months.

The VIVID trial enrolled 162 patients at 30 sites between 2020 and 2021. Primary safety and efficacy endpoints were met and will be available for presentation at the VIVA/VEINS meeting.

First-in-Human: Safety and Performance of the Akura Medical Thrombectomy System in Treating Venous ThromboembolismPresented by: Jay Mathews, MD, MS

A first-in-human, prospective, single-arm study enrolled five patients at two sites in Tbilisi, Georgia, in March and April 2023 to evaluate the safety and performance of percutaneous mechanical thrombectomy using the Akura Medical Thrombectomy System (Akura Medical). The Akura system is a low-profile system that combines targeted clot removal with a platform capable of providing objective data on hemodynamics to help clinicians understand the relationship between thrombus removal and alleviation of pulmonary artery pressures.

The key inclusion criteria included medically eligible patients aged > 18 years with clinical symptoms consistent with acute pulmonary embolism (PE) or sPESI (simplified PE Severity Index) ≥ 1, with symptom onset ≤ 14 days, proximal PE confirmed by CTA, a stable heart rate < 130 bpm prior to procedure, and systolic blood pressure ≥ 90 mm Hg, with a right ventricular/left ventricular (RV/LV) ratio > 0.9. Five patients were enrolled, treated, and followed through 7-day follow-up.

The patients successfully received treatment with the Akura thrombectomy system to remove pulmonary thrombus in the pulmonary vasculature. The average procedure time from anesthesia start to closure was 117 ± 50 minutes, with an average fluoroscopy time of 30 ± 21 minutes (range, 13-68 minutes). Total blood loss was 247 ± 80 mL on average, with 189 ± 120 mL of contrast used per procedure. After 48 hours, the RV/LV ratio decreased by 0.35 from 1.29 ± 0.15 to 0.94 ± 0.12 (P < .05; 26.85% reduction). Through 7-day follow-up, there were no deaths, device-related major bleeding, or device-related adverse events.

The Akura thrombectomy system for PE appears safe, and preliminary evidence shows that this platform technology leads to a significant reduction in RV/LV ratio and thrombus burden.

Local Anti-Inflammation to Augment Deep Vein Thrombosis Intervention: 6-Month Results From the Open-Label Phase of the DEXTERITY-AFP TrialPresented by: David J. Dexter, MD

The DEXTERITY-AFP trial is a phase 2, multisite trial investigating Bullfrog microinfusion device (Mercator MedSystems, Inc.) perivenous injection of dexamethasone sodium phosphate injection, USP combined with contrast and at a dosage of 2 mL (6.4 mg) each 5 cm of treatment length to improve patency and postthrombotic syndrome (PTS) 6 months after thrombus removal in symptomatic deep vein thrombosis (DVT) spanning into at least the common femoral, femoral, and/or popliteal veins. In the first phase of the trial, 21 participants were enrolled and treated with dexamethasone for comparison to known historical data. In the second phase of the trial, 60 participants will be enrolled 1:1 in a dual-blinded, randomized controlled trial (RCT). DEXTERITY-AFP is the first known trial to investigate local drug delivery intended to reduce venous inflammation associated with DVT.

Of the 21 patients enrolled in the first phase of the trial, one patient withdrew after 1-month follow-up. The 20 patients remaining are 90% male, 60% have left-sided DVT, are 10.2 ± 0.7 days post–symptom onset, and average treatment length is 36 ± 2 cm. Thrombus extent was categorized as 75% iliofemoral and 25% femoropopliteal. Regarding safety, there were no Bullfrog (device)- or dexamethasone (drug)-related serious adverse events observed. The primary efficacy endpoint, clinically relevant loss of primary patency, will be examined as combined with the RCT phase. Of the 21 patients followed at 1 month, 19 (90.5%) had fully compressible and two had partially compressible common femoral veins. Other key secondary endpoint data for 20 participants with in-window, 6-month follow-up include reduction from baseline to 6 months in average Villalta score (7.3 ± 0.7 to 1.6 ± 0.4) and 10-point pain score (3.2 ± 0.7 to 0.5 ± 0.2). Mild PTS was observed in 1/20 (5.0%) patients with no moderate-severe PTS.

About the VIVA FoundationThe VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, strives to be the premier educator in the field. Our team of specialists in vascular medicine, interventional cardiology, interventional radiology, and vascular surgery is driven by the passion to advance the field and improve patient outcomes. Educational events presented by the VIVA Foundation have a distinct spirit of collegiality attained by synergizing collective talents to promote awareness and innovative therapeutic options for vascular disease worldwide.

To learn more about the VIVA Foundation, visit https://viva-foundation.Org/.

View original content to download multimedia:https://www.Prnewswire.Com/news-releases/late-breaking-clinical-trial-results-announced-at-the-veins-2023-301971783.Html

SOURCE The VIVA Foundation

The Treatment Of Post-Thrombotic Syndrome

1. Kahn SR, Galanaud JP, Vedantham S, Ginsberg JS: Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 2016; 41: 144–53 CrossRef MEDLINE PubMed Central 2. Kahn SR, Shrier I, Julian JA, et al.: Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698–707 CrossRef MEDLINE 3. Pollack AA, Wood EH: Venous pressure in the saphenous vein at the ankle in man during exercise and changes in posture. J Appl Physiol 1949; 1: 649–62 MEDLINE 4. Hach W: Das arthrogene Stauungssyndrom. Gefäßchirurgie 2003; 8: 227–33 CrossRef 5. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J: Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006; 63: S5–15 CrossRef MEDLINE 6. Brandjes DP, Buller HR, Heijboer H, et al.: Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759–62 CrossRef 7. Ginsberg JS, Hirsh J, Julian J, et al.: Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med 2001; 161: 2105–9 CrossRef MEDLINE 8. Villalta S, Bagatella P, Piccioli A, Lensing A, Prins M, Prandoni P: Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis 1994; 24: 158a. 9. Arnoldussen CW, de Graaf R, Wittens CH, de Haan MW: Value of magnetic resonance venography and computed tomographic venography in lower extremity chronic venous disease. Phlebology 2013; 28: 169–75 CrossRef MEDLINE 10. Tick LW, Doggen CJ, Rosendaal FR, et al.: Predictors of the post-thrombotic syndrome with non-invasive venous examinations in patients 6 weeks after a first episode of deep vein thrombosis. J Thromb Haemost 2010; 8: 2685–92 CrossRef MEDLINE 11. Kahn SR, Ginsberg JS: Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004; 164: 17–26 CrossRef MEDLINE 12. Chen JT, Comerota AJ: Detecting the association between residual thrombus and post-thrombotic classification of chronic venous disease with range regression. Rev Recent Clin Trials 2012; 7: 329–34 CrossRef CrossRef 13. Wienert V, Gerlach H, Gallenkemper G, et al.: Leitlinie: Medizinischer Kompressionsstrumpf (MKS). Phlebologie 2006; 35: 315–20. 14. Wienert V, Partsch H, Gallenkemper G, et al.: Leitlinie: Intermittierende pneumatische Kompression (IPK oder AIK) Entwicklungsstufe S2. Phlebologie 2005; 34: 176–80. 15. Frulla M, Marchiori A, Sartor D, Mosena L, Tormene D, Hartman L: Elastic stockings, hydroxyethylrutosides or both for the treatment of post-thrombotic syndrome. Thromb Haemost 2005; 93: 183–5. 16. Kolbach DN, Sandbrink MW, Neumann HA, Prins MH: Compression therapy for treating stage I and II (Widmer) post-thrombotic syndrome. Cochrane Database Syst Rev 2003: CD004177 CrossRef 17. Kahn SR, Comerota AJ, Cushman M, et al.: The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2014; 130: 1636–61 CrossRef MEDLINE 18. Kahn SR, Shapiro S, Wells PS, et al.: Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383: 880–8 CrossRef 19. O'Meara S, Cullum N, Nelson EA, Dumville JC: Compression for venous leg ulcers. Cochrane Database Syst Rev 2012; 11: CD000265 CrossRef 20. Morling JR, Yeoh SE, Kolbach DN: Rutosides for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev 2015 CrossRef CrossRef 21. Kahn SR, Shrier I, Shapiro S, et al.: Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. CMAJ 2011; 183: 37–44 CrossRef MEDLINE PubMed Central 22. Neglén P, Hollis KC, Olivier J, Raju S: Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. J Vasc Surg 2007; 46: 979–90 CrossRef MEDLINE 23. Raju S, Darcey R, Neglen P: Unexpected major role for venous stenting in deep reflux disease. J Vasc Surg 2010; 51: 401–8 CrossRef MEDLINE 24. Palma EC, Esperon R: Vein transplants and grafts in the surgical treatment of the postphlebitic syndrome. J Cardiovasc Surg 1960; 1: 94–107. 25. Garg N, Gloviczki P, Karimi KM, et al.: Factors affecting outcome of open and hybrid reconstructions for nonmalignant obstruction of iliofemoral veins and inferior vena cava. J Vasc Surg 2011; 53: 383–93 CrossRef MEDLINE 26. Neglén P, Berry MA, Raju S: Endovascular surgery in the treatment of chronic primary and post-thrombotic iliac vein obstruction. Eur J Vasc Endovasc Surg 2000; 20: 560–71 CrossRef MEDLINE 27. Hartung O, Loundou AD, Barthelemy P, Arnoux D, Boufi M, Alimi YS: Endovascular management of chronic disabling ilio-caval obstructive lesions: long-term results. Eur J Vasc Endovasc Surg 2009; 38: 118–24 CrossRef MEDLINE 28. Neglen P, Tackett TP, Jr., Raju S: Venous stenting across the inguinal ligament. J Vasc Surg 2008; 48: 1255–61 CrossRef MEDLINE 29. Comerota AJ, Charles J, Tegtmeyer MD: Annual Lecture: Contemporary concepts in the management of acute iliofemoral DVT and chronic post-thrombotic iliofemoral venous obstruction – ISET 2013 – 25th annual international symposium on endovascular therapy. Www.Prolibraries.Com/player/?Libname=iset&sessionID=2961# (last accessed on 11 October 2016). 30. Jalaie H, Arnoldussen C, Barbati M, et al.: What predicts outcome after recanalization of chronic venous obstruction: hemodynamic factors, stent geometry, patient selection, anticoagulation or other factors? Phlebology 2014; 29: 97–103 CrossRef MEDLINE 31. Jalaie H, Schleimer K, Barbati ME, et al.: Interventional treatment of postthrombotic syndrome. Gefässchirurgie 2016; 21(Suppl 2): 37–44. CrossRef MEDLINE PubMed Central 32. De Wolf MA, de Graaf R, Kurstjens RL, Penninx S, Jalaie H, Wittens CH: Short-term clinical experience with a dedicated venous nitinol stent: initial results with the sinus-venous stent. Eur J Vasc Endovasc Surg 2015; 50: 518–26 CrossRef MEDLINE 33. Kistner RL: Surgical repair of venous valve. Straub Clin Proc 24 1968: 41–3. 34. Masuda EM, Kistner RL: Long-term results of venous valve reconstruction: a four- to twenty-one-year follow-up. J Vasc Surg 1994; 19: 391–403 CrossRef 35. Taheri SA, Elias SM, Yacobucci GN, Heffner R, Lazar L: Indications and results of vein valve transplant. J Cardiovasc Surg 1986; 27: 163–8. 36. Neglen P, Hollis KC, Raju S: Combined saphenous ablation and iliac stent placement for complex severe chronic venous disease. J Vasc Surg 2006; 44: 828–33 CrossRef MEDLINE 37. Lugli M, Guerzoni S, Garofalo M, Smedile G, Maleti O: Neovalve construction in deep venous incompetence. J Vasc Surg 2009; 49: 156–62 CrossRef MEDLINE 38. Diagnostik und Therapie des postthrombotischen Syndroms (einschließlich Ulcus cruris) (S2). Leitlinien zu Diagnostik und Therapie in der Gefäßchirurgie. Berlin, Heidelberg: Springer 2008; 141–6. E1. Kahn SR, Ginsberg JS: The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 2002; 16: 155–65 CrossRef e2. Meissner MH, Moneta G, Burnand K, et al.: The hemodynamics and diagnosis of venous disease. J Vasc Surg 2007; 46 Suppl S: 4s–24s. E3. Baldwin MJ, Moore HM, Rudarakanchana N, Gohel M, Davies AH: Post-thrombotic syndrome: a clinical review. J Thromb Haemost 2013; 11: 795–805 CrossRef MEDLINE e4. Kahn SR, Kearon C, Julian JA, et al.: Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost 2005; 3: 718–23 CrossRef MEDLINE e5. Prandoni P, Lensing AW, Cogo A, et al.: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1–7 CrossRef MEDLINE e6. Comerota AJ, Grewal N, Martinez JT, et al.: Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. J Vasc Surg 2012; 55: 768–73 CrossRef MEDLINE e7. Hull RD, Marder VJ, Mah AF, Biel RK, Brant RF: Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med 2005; 118: 456–64 CrossRef MEDLINE e8. Padberg FT, Jr., Johnston MV, Sisto SA: Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. J Vasc Surg 2004; 39: 79–87 CrossRef MEDLINE e9. Henke PK, Comerota AJ: An update on etiology, prevention, and therapy of postthrombotic syndrome. J Vasc Surg 2011; 53: 500–9 CrossRef MEDLINE e10. Gruss J, Hiemer W: Bypass procedures for venous obstruction: Palma and May-Husni bypasses, Raju perforator bypass, prosthetic bypasses, primary and adjunctive arteriovenous fistulae. Surgical Management of Venous Diseases Baltimore, Md: Williams & Wilkins 1997; 289–305. E11. May R: The Palma operation with Gottlob's endothelium preserving suture. In: May R, Weber J, eds.: Pelvic and abdominal veins: progress in diagnostics and therapy. Excerpta Medica, Amsterdam; 1981: 192–7. E12. Husni EA: Reconstruction of veins: the need for objectivity. J Cardiovasc Surg 1983; 24: 525–8. E13. Halliday P, Harris J, May J: Femoro-femoral crossover grafts (Palma operation): a long-term follow-up study. Surgery of the veins. Grune & Stratton, Orlando 1985: 241–54. E14. AbuRahma AF, Robinson PA, Boland JP: Clinical, hemodynamic, and anatomic predictors of long-term outcome of lower extremity venovenous bypasses. J Vasc Surg 1991; 14: 635–44 CrossRef CrossRef e15. KJ Husfeldt: Venous replacement with gore-tex prosthesis: experimental and first clinical results: In : May R, Weber J, eds.: Pelvic and abdominal veins: progress in diagnostics and therapy. Amsterdam: Excerpta Medica 1981; 249–58. E16. Dale WA, Harris J, Terry RB: Polytetrafluoroethylene reconstruction of the inferior vena cava. Surgery 1984; 95: 625–30 MEDLINE e17. Gloviczki P, Pairolero PC, Toomey BJ, et al.: Reconstruction of large veins for nonmalignant venous occlusive disease. J Vasc Surg 1992; 16: 750–61 CrossRef CrossRef e18. Alimi YS, DiMauro P, Fabre D, Juhan C: Iliac vein reconstructions to treat acute and chronic venous occlusive disease. J Vasc Surg 1997; 25: 673–81 CrossRef e19. Blättler W, Blättler IK: Relief of obstructive pelvic venous symptoms with endoluminal stenting. J Vasc Surg 1999; 29: 484–8 CrossRef e20. Hood DB, Alexander JQ: Endovascular management of iliofemoral venous occlusive disease. Surg Clin North Am 2004; 84: 1381–96 CrossRef MEDLINE e21. Knipp BS, Ferguson E, Williams DM, et al.: Factors associated with outcome after interventional treatment of symptomatic iliac vein compression syndrome. J Vasc Surg 2007; 46: 743–9 CrossRef MEDLINE e22. Nazarian GK, Bjarnason H, Dietz CA Jr, Bernadas CA, Hunter DW: Iliofemoral venous stenoses: effectiveness of treatment with metallic endovascular stents. Radiology 1996; 200: 193–9 CrossRef MEDLINE e23. Oguzkurt L, Tercan F, Ozkan U, Gulcan O: Iliac vein compression syndrome: outcome of endovascular treatment with long-term follow-up. Eur J Radiol 2008; 68: 487–92 CrossRef MEDLINE e24. O'Sullivan GJ, Semba CP, Bittner CA, et al.: Endovascular management of iliac vein compression (May-Thurner) syndrome. J Vasc Interv Radiol 2000; 11: 823–36 CrossRef e25. Raju S, Hollis K, Neglen P: Obstructive lesions of the inferior vena cava: clinical features and endovenous treatment. J Vasc Surg 2006; 44: 820–7 CrossRef MEDLINE e26. Razavi MK, Hansch EC, Kee ST, Sze DY, Semba CP, Dake MD: Chronically occluded inferior venae cavae: endovascular treatment. Radiology 2000; 214: 133–8 CrossRef MEDLINE e27. Te Riele WW, Overtoom TT, van den Berg JC, van de Pavoordt ED, de Vries JP: Endovascular recanalization of chronic long-segment occlusions of the inferior vena cava: midterm results. J Endovasc Ther 2006; 13: 249–53 CrossRef MEDLINE e28. Comerota AJ, Grewal NK, Thakur S, Assi Z: Endovenectomy of the common femoral vein and intraoperative iliac vein recanalization for chronic iliofemoral venous occlusion. J Vasc Surg 2010; 52: 243–7 CrossRef MEDLINE e29. Vogel D, Comerota AJ, Al-Jabouri M, Assi ZI: Common femoral endovenectomy with iliocaval endoluminal recanalization improves symptoms and quality of life in patients with postthrombotic iliofemoral obstruction. J Vasc Surg 2012; 55: 129–35 CrossRef MEDLINE e30. Gloviczki P, Kalra M, Duncan AA, Oderich GS, Vrtiska TJ, Bower TC: Open and hybrid deep vein reconstructions: to do or not to do? Phlebology 2012; 27: 103–6 CrossRef e31. Eklof B: Temporary arteriovenous fistula in reconstruction of iliac vein obstruction using PTFE grafts. Controversies in the management of venous disorders, London, UK: Butterworths 1989: 280–90. E32. Ijima H, Kodama M, Hori M: Temporary arteriovenous fistula for venous reconstruction using synthetic graft: a clinical and experimental investigation. J Cardiovasc Surg 1985; 26: 131–6. E33. Okadome K, Muto Y, Eguchi H, Kusaba A, Sugimachi K: Venous reconstruction for iliofemoral venous occlusion facilitated by temporary arteriovenous shunt. Long-term results in nine patients. Arch Surg 1989; 124: 957–60 CrossRef MEDLINE e34. Kistner RL: Surgical technique of external venous valve repair. Straub Found Proc 1990; 55: 15–6. E35. Us M, Basaran M, Sanioglu S, et al.: The use of external banding increases the durability of transcommissural external deep venous valve repair. Eur J Vasc Endovasc Surg 2007; 33: 494–501 CrossRef MEDLINE e36. Taheri SA, Lazar L, Elias S, Marchand P, Heffner R: Surgical treatment of postphlebitic syndrome with vein valve transplant. Am J Surg 1982; 144: 221–4 CrossRef e37. Nayak L, Hildebolt CF, Vedantham S: Postthrombotic syndrome: feasibility of a strategy of imaging-guided endovascular intervention. J Vasc Interv Radiol 2012; 23: 1165–73 CrossRef MEDLINE e38. Bond RT, Cohen JM, Comerota A, Kahn SR: Surgical treatment of moderate-to-severe post-thrombotic syndrome. Ann Vasc Surg 2013; 27: 242–58 CrossRef MEDLINE e39. Kleinspehn E, Kühme T, Atlihan G, Gebhardt C, Debus ES: Open surgical procedures for the treatment of post thrombotic syndrome (PTS). Gefässchirurgie 2016; 21: 64–5. E40. Kalra M, Gloviczki P, Noel AA, et al.: Subfascial endoscopic perforator vein surgery in patients with post-thrombotic venous insufficiency—is it justified? Vasc Endovascular Surg 2002; 36: 41–50.

Deep Vein Thrombosis

Swelling and pain in one of your legs, skin that looks red or discolored, and feels warm-- these symptoms can be caused by a blood clot in a vein deep inside your body, usually in one of your legs. It's called deep vein thrombosis, or DVT.

All our veins have small valves ]]>

Hide Video Transcript

[MUSIC PLAYING]

SPEAKER

Swelling and pain in one of your legs, skin that looks red or discolored, and feels warm-- these symptoms can be caused by a blood clot in a vein deep inside your body, usually in one of your legs. It's called deep vein thrombosis, or DVT.

All our veins have small valves latest videos on DVT

Load More

---